1 day Ago By ABMN Staff
Sarepta Therapeutics ( NASDAQ:SRPT – Get Free Report ) had its price target hoisted by stock analysts at UBS Group from $173.00 to $188.00 in a research note issued on Tuesday.
The brokerage presently has a “buy” rating on the biotechnology company’s stock. UBS Group’s price target suggests a potential upside of 50.39% from the stock’s previous close.
Other research analysts have also recently issued research reports about the stock. Morgan Stanley reiterated an “overweight” rating and issued a $165.00 price target on shares of Sarepta Therapeutics in a report on Friday, June 21st.
Needham & Company LLC reaffirmed a “buy” rating and set a $235.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, June 27th. BMO Capital Markets lifted their target price on Sarepta Therapeutics from $170.
00 to $200.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. Bank of America boosted their target price on Sarepta Therapeutics from $166.
00 to $213.00 and gave the company a “buy” rating in a research note on Friday, June 21st. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $181.
00 price objective on shares of Sarepta Therapeutics in a report on Friday, September 6th. Three equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $187.
39. Read Our Latest Report on Sarepta Therapeutics Sarepta Therapeutics Stock Performance Sarepta Therapeutics ( NASDAQ:SRPT – Get Free Report ) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.
07 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06.
Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%.
The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million.
During the same quarter last year, the firm posted ($0.27) earnings per share. Sarepta Therapeutics’s revenue was up 38.
9% compared to the same quarter last year. On average, research analysts predict that Sarepta Therapeutics will post 1.47 EPS for the current year.
Insider Transactions at Sarepta Therapeutics In related news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, with a total value of $4,955,684.
40. Following the completion of the transaction, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20.
The purchase was disclosed in a document filed with the SEC, which is available through this link . In related news, Director Michael Andrew Chambers purchased 37,038 shares of the stock in a transaction on Friday, August 16th. The shares were purchased at an average cost of $133.
80 per share, with a total value of $4,955,684.40. Following the acquisition, the director now directly owns 284,034 shares in the company, valued at $38,003,749.
20. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website . Also, EVP Ryan Edward Brown sold 38,957 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th.
The stock was sold at an average price of $161.61, for a total value of $6,295,840.77.
Following the sale, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The disclosure for this sale can be found here .
In the last three months, insiders sold 52,801 shares of company stock worth $8,399,586. 7.70% of the stock is owned by company insiders.
Institutional Inflows and Outflows Large investors have recently added to or reduced their stakes in the company. Clearbridge Investments LLC boosted its holdings in Sarepta Therapeutics by 57.0% in the 2nd quarter.
Clearbridge Investments LLC now owns 237,354 shares of the biotechnology company’s stock valued at $37,502,000 after purchasing an additional 86,138 shares during the period. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $4,771,000. Cetera Investment Advisers grew its position in Sarepta Therapeutics by 8.
5% during the second quarter. Cetera Investment Advisers now owns 13,013 shares of the biotechnology company’s stock worth $2,056,000 after buying an additional 1,022 shares in the last quarter. Truist Financial Corp increased its stake in Sarepta Therapeutics by 86.
5% during the 2nd quarter. Truist Financial Corp now owns 4,003 shares of the biotechnology company’s stock worth $632,000 after acquiring an additional 1,857 shares during the period. Finally, EP Wealth Advisors LLC raised its holdings in Sarepta Therapeutics by 2.
1% in the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after acquiring an additional 103 shares in the last quarter. Institutional investors own 86.
68% of the company’s stock. Sarepta Therapeutics Company Profile ( Get Free Report ) Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
See Also Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
